{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:27:15Z","timestamp":1791833235644,"version":"4.3.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>To investigate the role of mpMRI and high PIRADS score as independent triggers in the qualification of patients with ISUP 1 prostate cancer on biopsy to radical prostatectomy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Between January 2017 and June 2019, 494 laparoscopic radical prostatectomies were performed in our institution, including 203 patients (41.1%) with ISUP 1 cT1c-2c PCa on biopsy. Data regarding biopsy results, digital rectal examination, PSA, mpMRI and postoperative pathological report have been retrospectively analysed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In 183 cases (90.1%) mpMRI has been performed at least 6\u00a0weeks after biopsy. Final pathology revealed ISUP Gleason Grade Group upgrade in 62.6% of cases. PIRADS 5, PIRADS 4 and PIRADS 3 were associated with Gleason Grade Group upgrade in 70.5%, 62.8%, 48.3% of patients on final pathology, respectively. Within PIRADS 5 group, the number of upgraded cases was statistically significant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>PIRADS score correlates with an upgrade on final pathology and may justify shared decision of radical treatment in patients unwilling to repeated biopsies. However, the use of PIRADS 5 score as a sole indicator for prostatectomy may result in nonnegligible overtreatment rate.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12894-021-00850-3","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T09:02:48Z","timestamp":1621328568000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The role of mpMRI in qualification of patients with ISUP 1 prostate cancer on biopsy to radical prostatectomy"],"prefix":"10.1186","volume":"21","author":[{"given":"\u0141ukasz","family":"Nyk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Tayara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Z\u0105bkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Kryst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneta","family":"Andrychowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Malewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,18]]},"reference":[{"key":"850_CR1","unstructured":"World Health Organization International Agency for Research on Cancer (IARC). GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. Homepage on the internet; 2012 [cited 2016 Apr 23]. http:\/\/globocan.iarc.fr\/Pages\/fact_sheets_cancer.aspx."},{"issue":"3","key":"850_CR2","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/j.1464-410X.2012.11597.x","volume":"111","author":"MR Cooperberg","year":"2013","unstructured":"Cooperberg MR, Ramakrishna NR, Duff SB, Hughes KE, Sadownik S, Smith JA, et al. Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis. BJU Int. 2013;111(3):437\u201350.","journal-title":"BJU Int"},{"key":"850_CR3","unstructured":"EAU Guidelines. Edn. Presented at the EAU Annual Congress Amsterdam, 2020. ISBN 978-94-92671-07-3."},{"key":"850_CR4","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1200\/JCO.2014.55.1192","volume":"33","author":"L Klotz","year":"2015","unstructured":"Klotz L, Vesprini D, Sethukavalan P, Jethava V, Zhang L, Jain S, et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol. 2015;33:272\u20137.","journal-title":"J Clin Oncol"},{"issue":"4","key":"850_CR5","first-page":"CD012663","volume":"4","author":"FH Drost","year":"2019","unstructured":"Drost FH, Osses DF, Nieboer D, Steyerberg EW, Bangma CH, Roobol MJ, et al. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database Syst Rev. 2019;4(4):CD012663.","journal-title":"Cochrane Database Syst Rev"},{"key":"850_CR6","first-page":"237","volume":"68","author":"AA Grasso","year":"2016","unstructured":"Grasso AA, Cozzi G, Lorenzis DE, Ceruti C, Crivellaro S, Falsaperla M, et al. Multicenter analysis of pathological outcomes of patients eligible for active surveillance according to PRIAS criteria. Minerva Urol Nefrol. 2016;68:237\u201341.","journal-title":"Minerva Urol Nefrol"},{"issue":"5","key":"850_CR7","doi-asserted-by":"publisher","first-page":"202.e1","DOI":"10.1016\/j.urolonc.2015.01.023","volume":"33","author":"A Walton Diaz","year":"2015","unstructured":"Walton Diaz A, Shakir NA, George AK, Rais-Bahrami S, Turkbey B, Rothwax JT, et al. Use of serial multiparametric magnetic resonance imaging in the management of patients with prostate cancer on active surveillance. Urol Oncol. 2015;33(5):202.e1-202.e7.","journal-title":"Urol Oncol"},{"key":"850_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.urology.2017.03.048","volume":"106","author":"D Olvera-Posada","year":"2017","unstructured":"Olvera-Posada D, Welk B, McClure JA, Winick-Ng J, Izawa JI, Pautler SE. The impact of multiple prostate biopsies on risk for major complications following radical prostatectomy: a population-based cohort study. Urology. 2017;106:125\u201332.","journal-title":"Urology"},{"key":"850_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/ijir.2012.9","volume":"24","author":"P Sooriakumaran","year":"2012","unstructured":"Sooriakumaran P, Calaway A, Sagalovich D, Roy S, Srivastava A, Joneja J, et al. The impact of multiple biopsies on outcomes of nerve-sparing robotic-assisted radical prostatectomy. Int J Impot Res. 2012;24:161\u20134.","journal-title":"Int J Impot Res"},{"key":"850_CR10","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/bju.13002","volume":"116","author":"KS Murray","year":"2015","unstructured":"Murray KS, Bailey J, Zuk K, Lopez-Corona E, Thrasher JB. A prospective study of erectile function after transrectal ultrasonography-guided prostate biopsy. BJU Int. 2015;116:190\u20135.","journal-title":"BJU Int"},{"issue":"6","key":"850_CR11","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1097\/01.ju.0000158155.33890.e7","volume":"173","author":"MR Cooperberg","year":"2005","unstructured":"Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, Du Chane J, et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol. 2005;173(6):1938\u201342.","journal-title":"J Urol"},{"issue":"3","key":"850_CR12","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.eururo.2015.06.046","volume":"69","author":"JI Epstein","year":"2016","unstructured":"Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, et al. A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol. 2016;69(3):428\u201335.","journal-title":"Eur Urol"},{"issue":"6","key":"850_CR13","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1016\/j.juro.2008.08.027","volume":"180","author":"AE Thong","year":"2008","unstructured":"Thong AE, Shikanov S, Katz MH, Gofrit ON, Eggener S, Zagaja GP, et al. A single microfocus (5% or less) of Gleason 6 prostate cancer at biopsy\u2014can we predict adverse pathological outcomes? J Urol. 2008;180(6):2436\u201340.","journal-title":"J Urol"},{"issue":"2","key":"850_CR14","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.juro.2015.02.015","volume":"194","author":"KT Dinh","year":"2015","unstructured":"Dinh KT, Mahal BA, Ziehr DR, Muralidhar V, Chen YW, Viswanathan VB, et al. Incidence and predictors of upgrading and up staging among 10,000 contemporary patients with low risk prostate cancer. J Urol. 2015;194(2):343\u20139.","journal-title":"J Urol"},{"key":"850_CR15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.urology.2018.04.038","volume":"118","author":"DR Kaye","year":"2018","unstructured":"Kaye DR, Qi J, Morgan TM, Linsell S, Lane BR, Montie JE, et al. Michigan urological surgery improvement collaborative. Association between early confirmatory testing and the adoption of active surveillance for men with favorable-risk prostate cancer. Urology. 2018;118:127\u201333.","journal-title":"Urology"},{"issue":"4","key":"850_CR16","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1007\/s00330-011-2377-y","volume":"22","author":"JO Barentsz","year":"2012","unstructured":"Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, et al. ESUR prostate MR guidelines 2012. Eur Radiol. 2012;22(4):746\u201357.","journal-title":"Eur Radiol"},{"issue":"1","key":"850_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.eururo.2015.08.038","volume":"69","author":"JO Barentsz","year":"2016","unstructured":"Barentsz JO, Weinreb JC, Verma S, Thoeny HC, Tempany CM, Shtern F, et al. Synopsis of the PI-RADS v2 guidelines for multiparametric prostate magnetic resonance imaging and recommendations for use. Eur Urol. 2016;69(1):41\u20139.","journal-title":"Eur Urol"},{"key":"850_CR18","unstructured":"American College of Radiology. MR prostate imaging reporting and data system version 2.0. http:\/\/www.acr.org\/Quality-Safety\/Resources\/PIRADS\/. Accessed 4 Apr 2016."},{"issue":"4","key":"850_CR19","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.juro.2018.05.003","volume":"200","author":"SL Hofbauer","year":"2018","unstructured":"Hofbauer SL, Maxeiner A, Kittner B, Heckmann R, Reimann M, Wiemer L, et al. Validation of prostate imaging reporting and data system version 2 for the detection of prostate cancer. J Urol. 2018;200(4):767\u201373.","journal-title":"J Urol"},{"issue":"19","key":"850_CR20","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","volume":"378","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378(19):1767\u201377.","journal-title":"N Engl J Med"},{"issue":"10071","key":"850_CR21","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","volume":"389","author":"HU Ahmed","year":"2017","unstructured":"Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389(10071):815\u201322.","journal-title":"Lancet"},{"key":"850_CR22","doi-asserted-by":"publisher","first-page":"e1711","DOI":"10.1016\/S1569-9056(18)32038-4","volume":"17","author":"L Klotz","year":"2018","unstructured":"Klotz L, Loblaw A, Van Der Kwast T, Fleshner N, Ghai S, Chin J, et al. Active surveillance magnetic resonance imaging study (ASIST): results of a prospective, multicentre, randomized trial. Eur Urol Suppl. 2018;17:e1711\u20132.","journal-title":"Eur Urol Suppl"},{"issue":"13","key":"850_CR23","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/pros.23873","volume":"79","author":"S Verep","year":"2019","unstructured":"Verep S, Erdem S, Ozluk Y, Kilicaslan I, Sanli O, Ozcan F. The pathological upgrading after radical prostatectomy in low-risk prostate cancer patients who are eligible for active surveillance: how safe is it to depend on bioptic pathology? Prostate. 2019;79(13):1523\u20139.","journal-title":"Prostate"},{"issue":"9","key":"850_CR24","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1111\/iju.13138","volume":"23","author":"F Porpiglia","year":"2016","unstructured":"Porpiglia F, Cantiello F, De Luca S, De Pascale A, Manfredi M, Mele F, et al. Multiparametric magnetic resonance imaging and active surveillance: how to better select insignificant prostate cancer? Int J Urol. 2016;23(9):752\u20137.","journal-title":"Int J Urol"},{"issue":"8","key":"850_CR25","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1002\/jso.23584","volume":"109","author":"FB Thomsen","year":"2014","unstructured":"Thomsen FB, Brasso K, Klotz LH, R\u00f8der MA, Berg KD, Iversen P. Active surveillance for clinically localized prostate cancer\u2014a systematic review. J Surg Oncol. 2014;109(8):830\u20135.","journal-title":"J Surg Oncol"},{"issue":"4","key":"850_CR26","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.eururo.2014.10.010","volume":"67","author":"S Loeb","year":"2015","unstructured":"Loeb S, Bruinsma SM, Nicholson J, Briganti A, Pickles T, Kakehi Y, et al. Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification. Eur Urol. 2015;67(4):619\u201326.","journal-title":"Eur Urol"},{"issue":"1","key":"850_CR27","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.euo.2019.08.001","volume":"3","author":"S Goel","year":"2020","unstructured":"Goel S, Shoag JE, Gross MD, Al Hussein Al Awamlh B, Robinson B, Khani F, et al. Concordance between biopsy and radical prostatectomy pathology in the era of targeted biopsy: a systematic review and meta-analysis. Eur Urol Oncol. 2020;3(1):10\u201320.","journal-title":"Eur Urol Oncol"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-021-00850-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-021-00850-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-021-00850-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T21:13:36Z","timestamp":1699046016000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-021-00850-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,18]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["850"],"URL":"https:\/\/doi.org\/10.1186\/s12894-021-00850-3","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,18]]},"assertion":[{"value":"13 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Since I am managing director of urological clinic, I decide about the inclusion of patients to the study. All patients signed the informed consent that their medical data might be used in the future as part of retrospective study. The analyzed datasets were anonymised before we used it for the purpose of current study. According to the Act of 6 September 2001 Pharmaceutical Law the study was qualified as noninterventional observation study. Thus, this study did not require approval by Ethics Committee and registration in Central Register of Clinical Studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"82"}}